CTRI/2024/08/071776Not yet recruitingUnknown
To study the efficacy of Cabergoline as an adjunct to Metformin in management of overweight & obese women with PCOS
il0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Women diagnosed with PCOS by Rotterdam
- •criteria, Age 16-35 years, BMI 23-35 kg/m2, Willing to participate in the study
Exclusion Criteria
- •Patients with other endocrine disorders such as
- •Cushing’s Syndrome, acromegaly, pituitary
- •adenoma, etc , Women planning pregnancy in next 6 months, Intolerability to cabergoline, Not willing to participate
Investigators
Similar Trials
Unknown
Not Applicable
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant ProlactinomasResistance, DiseaseProlactinomaNCT03400865Zhebao Wu30
Completed
Phase 1
A Pilot Study of Cabergoline for the Treatment of Cocaine DependenceCocaine DependenceCocaine AbuseCocaine AddictionSubstance AbuseNCT01651364Baylor College of Medicine11
Completed
Phase 3
Treatment of uterine myoma.fibromyoma of uterus.Leiomyoma of uterusfibromyoma of uterusIRCT201403092624N12Vice chancellor for research ,Iran University of Medical Sciences.50
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLSRestless Legs SyndromeNCT00627003Pfizer43
Completed
Phase 3
A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLSRestless Legs SyndromeNCT00625547Pfizer361